Inflammatory bowel disease in the elderly: A focus on disease characteristics and treatment patterns

被引:6
|
作者
Mosli, Mahmoud [1 ]
Alghamdi, Maha [2 ]
Bokhary, Omar [2 ,3 ]
Alzahrani, Maria [2 ]
Takieddin, Siba [2 ]
Galai, Tala [2 ]
Alsahafi, Majid [1 ]
Saadah, Omar
机构
[1] King Abdulaziz Univ, Fac Med, Dept Internal Med, Jeddah, Saudi Arabia
[2] King Abdulaziz Univ, Fac Med, Jeddah, Saudi Arabia
[3] King Abdulaziz Univ, Fac Med, Dept Pediat, Jeddah, Saudi Arabia
来源
SAUDI JOURNAL OF GASTROENTEROLOGY | 2023年 / 29卷 / 04期
关键词
Crohn's disease; elderly; inflammatory bowel disease; Montreal classification; ulcerative colitis;
D O I
10.4103/sjg.sjg_503_22
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: As the population ages, the number of elderly inflammatory bowel disease (IBD) patients is expected to increase. The clinical features and therapeutic options for young and old patients may differ, as elderly IBD patients are likely to have different comorbidities and disease characteristics. The goal of this study was to examine the clinical aspects and therapeutic choices for elderly Saudi IBD patients. Methods: We conducted a retrospective study aimed at describing the demographic, clinical, and management characteristics of IBD in elderly patients (=60 years) who followed up at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. The data was extracted from the KAUH inflammatory bowel disease information system (IBDIS) registry. The primary outcome was to describe disease characteristics in accordance with the Montreal classification and the secondary outcomes were to describe treatment patterns and identify significant clinical associations. Results: Our data were collected from 76 patients who fulfilled the study inclusion criteria. Females outnumbered males (53.9% vs 46.1%) and the mean age was 51.5 +/- 9.7 years. Essential hypertension (26.3%) was the most common comorbidity followed by diabetes mellitus (23.6%), and malignant neoplasms (9.21%). More than half of the patients with Crohn's disease (CD) had disease onset after forty years of age. The most common form of disease distribution was ileocolonic disease (64.7%). Less than 17% of patients had a penetrating disease phenotype. About 88 percent of patients with UC presented >40 years of age. Approximately, half of the cohort had left-sided ulcerative colitis (UC) (48%), followed by pancolitis (40%). The most prescribed medication class for IBD was 5-aminosalicylic acid (5-ASA) derivatives (56.58%) followed by corticosteroids and immunosuppressive drugs. Conclusions: In Saudi Arabia, age-specific concerns including comorbidities and polypharmacy remain the major challenges in the management of elderly IBD patients.
引用
收藏
页码:212 / 218
页数:7
相关论文
共 50 条
  • [31] Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease
    Maronek, Martin
    Link, Rene
    Ambro, Lubos
    Gardlik, Roman
    CELLS, 2020, 9 (04)
  • [32] Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease
    Rufini, Sara
    Ciccacci, Cinzia
    Novelli, Giuseppe
    Borgiani, Paola
    PHARMACOGENOMICS, 2017, 18 (11) : 1095 - 1114
  • [33] Epidemiology of inflammatory bowel disease: Focus on Asia
    Ng, Siew C.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2014, 28 (03) : 363 - 372
  • [34] Neuroimmunomodulation in the Gut: Focus on Inflammatory Bowel Disease
    Bernardazzi, Claudio
    Pego, Beatriz
    de Souza, Heitor Siffert P.
    MEDIATORS OF INFLAMMATION, 2016, 2016
  • [36] Inflammatory Bowel Disease Drugs: A Focus on Autophagy
    Hooper, Kirsty M.
    Barlow, Peter G.
    Stevens, Craig
    Henderson, Paul
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (01): : 118 - 127
  • [37] Inflammatory Bowel disease - Mucosal healing in Focus
    Drohsin, Susanne
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2012, 50 (10): : A2 - A4
  • [38] Treatment of inflammatory bowel disease
    Nikolaus, S.
    Schreiber, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (05) : 205 - 208
  • [39] Inflammatory bowel disease treatment
    Jakub Fichna
    Pharmacological Reports, 2016, 68 : 787 - 788
  • [40] Inflammatory bowel disease treatment
    Fichna, Jakub
    PHARMACOLOGICAL REPORTS, 2016, 68 (04) : 787 - 788